Ruxolitinib, a selective JAK1/2 inhibitor approved by the FDA for myeloproliferative neoplasms, is being studied in relapsed B-cell lymphoma and PTCL (NCT01431209). Here, JAK1 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.